Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could offer a significant development for weight treatment. Early patient investigations have shown substantial losses in visceral tissue, possibly exceeding other body composition therapies . However , more assessment is ne